Viking Therapeutics, Inc. (LON:0VQA)

Viking Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	26.68	55.52	36.63	26.37	29.12
Short-Term Investments	875.94	306.56	118.85	175.73	219.27
Cash & Short-Term Investments	902.61	362.08	155.49	202.1	248.39
Cash Growth	149.29%	132.87%	-23.07%	-18.63%	-9.89%
Prepaid Expenses	1.13	2.52	3.41	0.62	0.44
Other Current Assets	3.48	2.62	8.14	7.81	7.28
Total Current Assets	907.22	367.23	167.04	210.53	256.1
Property, Plant & Equipment	1	1.13	1.42	0.03	0.32
Long-Term Deferred Charges	0.06	0.11	0.04	0.08	0.05
Other Long-Term Assets	0.05	0.03	0.03	0.03	0.03
Total Assets	908.32	368.49	168.53	210.66	256.5
Accounts Payable	9.81	7.51	8.53	1.44	3.99
Accrued Expenses	17.11	11.3	13.11	7.31	7.81
Current Portion of Leases	0.49	0.32	0.3	0.03	0.33
Total Current Liabilities	27.41	19.14	21.95	8.78	12.13
Long-Term Leases	0.63	0.94	1.26	-	0.03
Total Liabilities	28.04	20.07	23.21	8.78	12.16
Common Stock	0	0	0	0	0
Additional Paid-In Capital	1,369	733.55	445.27	425.61	412.59
Retained Earnings	-487.91	-377.94	-292.05	-223.18	-168.19
Treasury Stock	-	-6.8	-6.8	-	-
Comprehensive Income & Other	-0.79	-0.39	-1.1	-0.55	-0.05
Shareholders' Equity	880.28	348.42	145.32	201.88	244.34
Total Liabilities & Equity	908.32	368.49	168.53	210.66	256.5
Total Debt	1.12	1.26	1.56	0.03	0.36
Net Cash (Debt)	901.49	360.82	153.92	202.07	248.03
Net Cash Growth	149.85%	134.42%	-23.83%	-18.53%	-9.80%
Net Cash Per Share	8.27	3.82	2.00	2.62	3.42
Filing Date Shares Outstanding	111.57	100.49	78.42	78.36	74.13
Total Common Shares Outstanding	111.57	100.11	78.26	78.25	73.22
Working Capital	879.8	348.09	145.09	201.75	243.98
Book Value Per Share	7.89	3.48	1.86	2.58	3.34
Tangible Book Value	880.28	348.42	145.32	201.88	244.34
Tangible Book Value Per Share	7.89	3.48	1.86	2.58	3.34

Source: S&P Capital IQ. Standard template. Financial Sources.